Navigation Links
IDM Pharma Provides Update of Product Pipeline and Announces Plans to Evaluate Strategic Alternatives for the Company
Date:12/14/2007

ope.

UVIDEM has been administered to 143 patients in clinical development. Patient enrollment has been completed in three other Phase 2 clinical trials including individuals with resected stage 2 or 3 melanoma and individuals with metastatic melanoma. Sanofi-aventis has worldwide marketing rights to UVIDEM in melanoma.

IDM-2101

The Company announced updated results in November 2007 from its Phase 2 trial in patients with non-small cell lung cancer (NSCLC) who were vaccinated with IDM-2101, compared to a parallel external control group of non-vaccinated patients. Updated one-year survival in patients treated with IDM-2101 was 60 percent, compared to 49 percent in a group of seventy-two patients who were HLA-A2 negative but otherwise comparable (external comparator group). Median survival for patients treated with IDM-2101 was 17.3 months compared to 12.0 months for patients in the comparator group.

Based on this encouraging survival trend, the Company has continued to work with outside consultants and clinical advisors to develop a next-step clinical plan for IDM-2101. The Company expects to have the clinical plan completed by the end of 2007.

About IDM Pharma

IDM Pharma is focused on the development of innovative cancer products that either destroy cancer cells by activating the immune system or prevent tumor recurrence by triggering a specific adaptive immune response. IDM Pharma is dedicated to maximizing the full therapeutic and commercial potential of each of its innovative products to address the needs of patients and the physicians who treat these patients.

At September 30, 2007 the Company had cash and cash equivalents of $33.2 million.

For more information about the Company and its products, visit http://www.idm-pharma.com.

Forward-Looking Statements

This press release and the presentation described in this press release include forward
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... and BOSTON , May 24, 2013 ... company, is pleased to announce that it has engaged Mr ... Company,s business development capabilities in Japan and ... years of experience in business development, licensing and alliance management in ... Pharma ( Japan ), Nippon Roche and Tanabe Seiyaku ...
(Date:5/23/2013)... OAKS, Calif. , May 23, 2013 Amgen ... Bank 38 th Annual  Healthcare Conference on Thursday, May ... Boston , beginning at 9:20 a.m. Eastern Daylight Time. ... Relations at Amgen, will present at the conference. Live audio ... on Amgen,s website, www.amgen.com , under Investors. A replay ...
(Date:5/23/2013)... 2013  A recently published clinical study conducted at ... , demonstrates that 3D mammography (breast tomosynthesis) significantly ... The study, "Implementation of Breast Tomosynthesis in ... by Stephen L. Rose , MD, ... American Journal of Roentgenology (AJR). The AJR is ...
Breaking Medicine Technology:Heptares Augments Business Development Capabilities in Japan and Other Asian Territories 2First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 2First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 3
... /PRNewswire-iReach/ -- CoLucid Pharmaceuticals, Inc., a ... has raised $7.5 million of a planned $9.5 ... to support further late stage development of lasmiditan.  ... Associates, Care Capital, Pearl Street Venture Funds and ...
... DIEGO, Aug. 30, 2011 aTyr Pharma , ... to aTyr,s leadership team of Dr. Jeffrey Greve, as ... president, intellectual property. Drs. Greve and Cubitt will support ... on Physiocrine biology. Physiocrines are naturally occurring human proteins ...
Cached Medicine Technology:CoLucid Pharmaceuticals Raises $7.5 Million of Planned $9.5 Million 2aTyr Pharma Expands Leadership Team to Advance New Breakthrough Medicines Based on Physiocrine Biology 2aTyr Pharma Expands Leadership Team to Advance New Breakthrough Medicines Based on Physiocrine Biology 3
(Date:5/24/2013)... 24 (HealthDay News) -- People with high levels of ... die of liver disease than those with lower levels, ... cadmium in urine is evidence of long-term exposure to ... and tobacco smoke, the Johns Hopkins researchers explained. ... cadmium directly causes liver disease but instead suggest an ...
(Date:5/24/2013)... Seattle, WA (PRWEB) May 24, 2013 ... consider when picking out a home security monitoring ... comparisons help make 6Webs.com the useful resource consumers prefer ... recently completed performing their evaluations of the leading wireless ... home security companies are rated on a number of ...
(Date:5/24/2013)... 2013 According to a May 15, 2013 ... Leads to Spikes in Plastic Surgery Requests,” a ... prevalence of facial plastic surgery and cosmetic improvements ... become keenly aware of the need to look good online ... Google and even Skype's video chat feature (Go to goo.gl/WO0PR). ...
(Date:5/24/2013)... LONG BEACH, CA (PRWEB) May 24, 2013 ... California's health care education community, proudly participated in festivities ... on April 19-21. The event provided the perfect backdrop ... and facilities at 236 E. 3rd Street, housed in ... the Arts Building. , ACC was an active exhibitor ...
(Date:5/24/2013)... May 24 (HealthDay News) -- The number of ... after spending time in an emergency room has ... research. The study, conducted by researchers at ... and Health Services in Washington, D.C., found that ... on average before being admitted to the ICU. ...
Breaking Medicine News(10 mins):Health News:High Cadmium Levels May Raise Risk for Dying From Liver Disease: Study 2Health News:2013 Best Wireless Security System Providers Reported by 6Webs.com 2Health News:Facebook and Google – Is Social Media Driving Demand for Plastic Surgery? 2Health News:American Career College Revs Up Community Support During Toyota Grand Prix of Long Beach 2Health News:Sharp Rise in ICU Admissions From U.S. Emergency Rooms 2
... IM), As part of an ongoing commitment to ... Portland, Ore. today announced its,investment in the world,s most ... be the first medical center on the West,Coast - ... to house IMRISneuro; a fully,integrated operating room that combines ...
... corporate infrastructure and provide ... tactical and strategic market advantages, HARRISBURG, Pa., ... a rapidly growing, national medical management,firm has promoted two ... Meghan Harris, MS, is KePRO,s new Vice,President, Informatics and ...
... (Nasdaq: ONXX ) today announced that it ... Conference on Thursday,May 1, at 8:00 a.m. Eastern ... of the presentation on our website at:, ... listeners log on 15 minutes early in order ...
... Protect Against Healthcare and Employment,Discrimination, BAYSIDE, ... Association, Inc. (TSA), hailed today,s vote in ... Genetic,Information Nondiscrimination Act (GINA), to ban genetic ... of Representatives passed GINA,in April 2007., ...
... Bliss Products Bring Blissful Comfort to Mothers-to-Be, SAN ... at the,end of the first trimester -- this is ... can really start enjoying their pregnancy.,However, those, who wish ... turn to magic. Mommy,s Bliss Morning Sickness Magic(TM) is,the ...
... and Quality of Care Rank as Top Factors in Choosing the Right ... ... the age of 50 expect an immediate family member to move into a ... of,65 expect the same for themselves, according to a new national survey of,American ...
Cached Medicine News:Health News:Providence St. Vincent bringing IMRISneuro, the world's most advanced surgical MRI to Portland, Oregon 2Health News:Providence St. Vincent bringing IMRISneuro, the world's most advanced surgical MRI to Portland, Oregon 3Health News:KePRO Appoints Two New IT Vice Presidents 2Health News:KePRO Appoints Two New IT Vice Presidents 3Health News:Tourette Syndrome Association Applauds the Passage of Genetic Information Nondiscrimination Act 2Health News:Morning Sickness Magic(TM) - An Effective Natural Approach to Morning Sickness 2Health News:New National Survey: 84% of Americans Over 50 Expect a Family Member to Move into an Assisted Living Community Within the Next 10 Years 2
Shandon Paraffin Block Cartons...
The Modular Storage Drawers provide permanent storage and identification of up to 165 embedding rings or 250 cassettes per drawer....
Cardboard Block Filing Cabinet is an economical solution for block storage needs....
Shandon Carousel Cassette MicroWriter™ is a carousel-type cassette marking system....
Medicine Products: